Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 3/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | CDKN1A | P38936 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843024 | 0.90 | TMIGD3 (0.46) | KDM4EKMT2ATMIGD3ADORA1ALDH1A1 | |
| SCHEMBL2837248 | 0.90 | ALDH1A1 (0.61) | KDM4EKMT2ATMIGD3ADORA1ALDH1A1 | |
| SCHEMBL2838028 | 0.89 | ALDH1A1 (0.57) | KDM4EKMT2ATMIGD3ADORA1ALDH1A1 | |
| SCHEMBL13475914 | 0.88 | TMIGD3 (0.45) | KDM4EKMT2ATMIGD3ADORA1ALDH1A1 | |
| SCHEMBL2839683 | 0.88 | CDKN1A (0.56) | KDM4EKMT2ATMIGD3ADORA1ALDH1A1 | |
| SCHEMBL2837355 | 0.87 | BRD4 (0.55) | KDM4EKMT2ATMIGD3ADORA1ALDH1A1 | |
| SCHEMBL2837954 | 0.86 | TNKS (0.47) | KDM4EKMT2ATMIGD3ADORA1ALDH1A1 | |
| SCHEMBL13475911 | 0.84 | TNKS (0.49) | KDM4EKMT2ATMIGD3ADORA1ALDH1A1 | |
| SCHEMBL2833833 | 0.83 | FGFR1 (0.52) | KDM4EKMT2ATMIGD3ADORA1ALDH1A1 | |
| SCHEMBL8311455 | 0.82 | TMIGD3 (0.67) | KDM4EKMT2ATMIGD3ADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662814-B2 | 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-02-16 | — | — | US | disclosed |
| US-7662814-B2 | 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-02-16 | — | — | US | disclosed |
| EP-1590352-B1 | 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | ALMIRALL LAB (ES) | 2007-06-27 | — | — | EP | disclosed |
| US-20060229306-A1 | 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229306-A1 | 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors | PDE7B, PDE7A, PDE3A | KDM4E 2683/4885KMT2A 3746/4885TMIGD3 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.